Any current/future capex/capital investment/strategic investment?

Ongoing Greenfield expansion at Tarapur: Rs 100 crore CAPEX planned, expected to bring 50% capacity addition. Civil construction started December; completion and production expected in around 18 months (mid-2023 to H1 FY24). Funded through debt and internal accruals. Macrotech facility expansion completed December; commercial production starting Q1 FY23, expected to add ~50 crore in revenue once at full capacity. Increasing outsourced production with a target of 15% outsourced production by end of FY23; new vendor relationships established. Continuous process improvements and debottlenecking a

Future growth expectations in sales/revenue/volumes?

Company achieved 12% YoY revenue growth in Q3 FY22 to Rs. 81 crores and 21% for 9 months to Rs. 235 crores. Veterinary API business grew 25% YoY in Q3 FY22 and 37% for 9 months. Top 5 customers contribute ~21.5% and top 10 about one-third of sales. Growth driven by increased market penetration, volume growth rather than price hikes. Plans to increase product mix from 20-22 to ~30 products in next 3 years to fill new capacity. Expect to add Rs. 50-60 crores revenue from Macrotech capacity in FY23-24, plus growth via outsourcing and debottlenecking. Anticipate 20-25% growth rate before new green

Future growth expectations in earnings/operating earnings/profits/EPS?

Revenue growth is expected around 20%-25% annually, driven by volume growth and increased market share. Macrotech expansion will contribute roughly Rs 50 crore in revenues once fully utilized, aiding growth through FY23-24. Outsourcing production is targeted to reach 15% by end of FY23, supporting capacity and growth. Debottlenecking and process improvements will sustain near-term growth with CAPEX around Rs 6-8 crore annually. New product introductions aim to grow the product basket from 20-22 to about 30 in three years, broadening revenue sources. Margins currently impacted by commodity pric

IN US

Sale is live|00:00:00left today

NGL Fine Chem LtdQ4 FY23Pharmaceuticals & Biotechnology

NGL Fine Chem Ltd Q4 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹3,054P/E: 48.8Market Cap: ₹1.5K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→Company achieved 12% YoY revenue growth in Q3 FY22 to Rs. 81 crores and 21% for 9 months to Rs. 235 crores.
→Veterinary API business grew 25% YoY in Q3 FY22 and 37% for 9 months.
→Top 5 customers contribute ~21.5% and top 10 about one-third of sales.
→Growth driven by increased market penetration, volume growth rather than price hikes.
→Plans to increase product mix from 20-22 to ~30 products in next 3 years to fill new capacity.
→Expect to add Rs. 50-60 crores revenue from Macrotech capacity in FY23-24, plus growth via outsourcing and debottlenecking.
→Anticipate 20-25% growth rate before new greenfield plant becomes operational.
→Smaller/newer products (5-10 and 10-20 product categories) growing faster (~26%) than top 5 products (~21%).
→Expansion focused on increasing market share and new product commercialization.
→Capacity expansion constrained by long equipment delivery times; only one project currently underway.

Margin guidance

Category 3

→Revenue growth is expected around 20%-25% annually, driven by volume growth and increased market share.
→Macrotech expansion will contribute roughly Rs 50 crore in revenues once fully utilized, aiding growth through FY23-24.
→Outsourcing production is targeted to reach 15% by end of FY23, supporting capacity and growth.
→Debottlenecking and process improvements will sustain near-term growth with CAPEX around Rs 6-8 crore annually.
→New product introductions aim to grow the product basket from 20-22 to about 30 in three years, broadening revenue sources.
→Margins currently impacted by commodity price inflation are expected to normalize by Q1-Q2 FY23, restoring gross margins to 55%-57%.
→EBITDA margin stood at 15.4% in Q3 FY22, with profitability expected to improve post normalization of input costs.
→Focus remains on widening product mix, market penetration, cost competitiveness, and reliable supply to maintain earnings growth.

3 more insights locked — sign up free to unlock

Fundraise plans

- As per the discussion on Page 8, the company has budgeted a 100 crore loan plus internal accruals for the new project. - There is a mention of re-evaluating cost overruns for the new project due to rising steel and commodity prices; the extent of cost overrun is expected to be not more than 10%. - There is no explicit mention of any new fundraising through equity. - The company maintains a net debt-free position as stated on Page 4. - No indication of immediate or planned debt or equity fundraising beyond the current budgeted loan and internal accruals for capex. In summary, the company plans to manage project funding through a combination of a 100 crore loan and internal accruals, with no new equity fundraising currently indicated.

Order book

Yes

The transcript does not explicitly mention the current or expected order book or pending orders for NGL Fine Chem Limited. However, relevant insights include: - The company has commitments to customers close to about three to four months ahead, indicating a forward order visibility for that duration. - There is strong volume demand and increased market penetration contributing to revenue growth. - Despite macroeconomic challenges, NGL is maintaining and expanding market share through reliable supply and quality service. - They are working on capacity expansion projects to meet growing customer demand. - Inventory levels have been managed proactively, with curtailment starting as raw material prices normalize. - The company plans to introduce 5 new molecules over the next year, aiming to increase its product basket and fill new capacity. No specific quantitative details on order book or pending orders were disclosed.

Capex plans

Yes

→Ongoing Greenfield expansion at Tarapur: Rs 100 crore CAPEX planned, expected to bring 50% capacity addition. Civil construction started December; completion and production expected in around 18 months (mid-2023 to H1 FY24). Funded through debt and internal accruals.
→Macrotech facility expansion completed December; commercial production starting Q1 FY23, expected to add ~50 crore in revenue once at full capacity.
→Increasing outsourced production with a target of 15% outsourced production by end of FY23; new vendor relationships established.
→Continuous process improvements and debottlenecking activities underway with normal CAPEX of Rs 6 to 8 crores annually for capacity enhancement and replacement.
→Strategic land holdings in Mahad and Ambernath for future expansions; no current EC applications as focus is on Tarapur project.
→Efforts planned for securing EC approvals well in advance for future projects within 7-8 years rolling plan.

How does NGL Fine Chem Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1NGL Fine Chem Ltd

Rev 2Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like NGL Fine Chem Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio